Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Lymphangioleiomyomatosis

• Feasibility of [11C]Acetate-Positron Emission Tomography (PET) in Lymphangioleiomyomatosis and Tuberous Sclerosis Complex
• Effect of Loratadine in Lymphangioleiomyomatosis
• Characterizing LAM With 11C-Choline PET/CT
• Glutamine PET Imaging in LAM
• Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial
• Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
• LAM Pilot Study With Imatinib Mesylate
• A Study of Nintedanib for LymphAngioleioMyomatosis (LAM)
• Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
• COLA: A Pilot Clinical Trial of COX-2 Inhibition in LAM and TSC
• Safety and Durability of Sirolimus for Treatment of LAM
• The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
• Safety of Simvastatin in LAM and TSC
• Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis
• Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
• Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
• Trial of Aromatase Inhibition in Lymphangioleiomyomatosis
• A Study to Determine the Safety and Effectiveness of RAD001 (Everolimus) in Patients With Lymphangioleiomyomatosis
• Doxycycline In Lymphangioleiomyomatosis (LAM)
• Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM)
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
• Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
• RAD001 Therapy of Angiomyolipomata in Patients With TS Complex and Sporadic LAM
• Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM
• Efficacy and Safety of Sirolimus for Treating Lymphangioleiomyomatosis (LAM)
• Treatment With Octreotide in Patients With Lymphangioleiomyomatosis